Impact of Acyclovir on Genital and Plasma HIV-1 RNA, Genital Herpes Simplex Virus Type 2 DNA, and Ulcer Healing among HIV-1–Infected African Women with Herpes Ulcers: A Randomized Placebo-Controlled Trial
Identifieur interne : 000A47 ( Main/Exploration ); précédent : 000A46; suivant : 000A48Impact of Acyclovir on Genital and Plasma HIV-1 RNA, Genital Herpes Simplex Virus Type 2 DNA, and Ulcer Healing among HIV-1–Infected African Women with Herpes Ulcers: A Randomized Placebo-Controlled Trial
Auteurs : Philippe Mayaud [Royaume-Uni] ; Jérôme Legoff ; Helen A. Weiss [Royaume-Uni] ; Gérard Grésenguet [République centrafricaine] ; Khonde Nzambi [Ghana] ; Hicham Bouhlal ; Eric Frost [Canada] ; Jacques Pépin [Canada] ; Jean-Elie Malkin [France] ; Richard J. Hayes [Royaume-Uni] ; David C. W. Mabey ; Laurent BélecSource :
- The Journal of Infectious Diseases [ 0022-1899 ] ; 2009-07-15.
Descripteurs français
- KwdFr :
- ADN viral (métabolisme), ARN viral (métabolisme), ARN viral (sang), Aciclovir (usage thérapeutique), Adolescent, Adulte, Antiviraux (usage thérapeutique), Femelle, Ghana (épidémiologie), Herpès génital (), Herpès génital (traitement médicamenteux), Herpès génital (épidémiologie), Herpèsvirus humain de type 2 (génétique), Herpèsvirus humain de type 2 (métabolisme), Humains, Infections à VIH (), Infections à VIH (virologie), Méthode en double aveugle, République centrafricaine (épidémiologie), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (métabolisme).
- MESH :
- génétique : Herpèsvirus humain de type 2, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- métabolisme : ADN viral, ARN viral, Herpèsvirus humain de type 2, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- sang : ARN viral.
- traitement médicamenteux : Herpès génital.
- usage thérapeutique : Aciclovir, Antiviraux.
- virologie : Infections à VIH.
- épidémiologie : Ghana, Herpès génital, République centrafricaine.
- Adolescent, Adulte, Femelle, Herpès génital, Humains, Infections à VIH, Méthode en double aveugle.
- Pascal (Inist)
- Wicri :
- geographic : Ghana, République centrafricaine.
- topic : Homme.
English descriptors
- KwdEn :
- AIDS, Aciclovir, Acyclovir (therapeutic use), Adolescent, Adult, Antiviral, Antiviral Agents (therapeutic use), Central African Republic (epidemiology), DNA, Viral (metabolism), Double-Blind Method, Female, Genital herpes, Ghana (epidemiology), HIV Infections (complications), HIV Infections (virology), HIV-1 (genetics), HIV-1 (metabolism), HIV-1 virus, Herpes Genitalis (complications), Herpes Genitalis (drug therapy), Herpes Genitalis (epidemiology), Herpesvirus 2, Human (genetics), Herpesvirus 2, Human (metabolism), Human, Human herpesvirus 2, Humans, Microbiology, RNA, Viral (blood), RNA, Viral (metabolism), Ulcer.
- MESH :
- chemical , blood : RNA, Viral.
- chemical , metabolism : DNA, Viral, RNA, Viral.
- chemical , therapeutic use : Acyclovir, Antiviral Agents.
- geographic , epidemiology : Central African Republic, Ghana.
- complications : HIV Infections, Herpes Genitalis.
- drug therapy : Herpes Genitalis.
- epidemiology : Herpes Genitalis.
- genetics : HIV-1, Herpesvirus 2, Human.
- metabolism : HIV-1, Herpesvirus 2, Human.
- virology : HIV Infections.
- Adolescent, Adult, Double-Blind Method, Female, Humans.
Abstract
BackgroundLittle is known about the impact of episodic treatment of herpes on human immunodeficiency virus type 1 (HIV-1) MethodsWomen from Ghana and the Central African Republic who had genital ulcers were enrolled in a randomized, double-blind, placebo-controlled trial of acyclovir plus antibacterials and were monitored for 28 days. Ulcer etiologies and detection of lesional HIV-1 RNA were determined by polymerase chain reaction (PCR). Cervicovaginal HIV-1 RNA and herpes simplex virus type 2 (HSV-2) DNA and plasma HIV-1 RNA were quantitated by real-time PCR. Primary analyses included 118 HIV-1–infected women with HSV-2 ulcers (54 of whom were given acyclovir and 64 of whom were given placebo) ResultsAcyclovir had little impact on (1) detection of cervicovaginal HIV-1 RNA (risk ratio [RR], 0.96; 95% confidence interval [CI], 0.8–1.2) at day 7 of treatment, (2) the mean cervicovaginal HIV-1 RNA load (−0.06 log10 copies/mL; 95% CI, −0.4 to 0.3 log10 copies/mL) at day 7 of treatment, or (3) the plasma HIV-1 RNA load (+0.09 log10 copies/mL; 95% CI, −0.1 to 0.3 log10 copies/mL) at day 14 of treatment. At day 7, women receiving acyclovir were less likely to have detectable lesional HIV-1 RNA (RR, 0.70; 95% CI, 0.4–1.2) or cervicovaginal HSV-2 DNA (RR, 0.69; 95% CI, 0.4–1.3), had a lower quantity of HSV-2 DNA (−0.99 log10 copies/mL; 95% CI, −1.8 to −0.2 log10 copies/mL), and were more likely to have a healed ulcer (RR, 1.26; 95% CI, 0.9–1.9) ConclusionEpisodic therapy for herpes reduced the quantity of cervicovaginal HSV-2 DNA and slightly improved ulcer healing, but it did not decrease genital and plasma HIV-1 RNA loads Trial registrationClinicalTrials.gov identifier NCT00158483
Url:
DOI: 10.1086/599991
Affiliations:
- Canada, France, Ghana, Royaume-Uni, République centrafricaine
- Angleterre, Grand Londres, Région du Grand Accra, Île-de-France
- Accra, Londres, Paris
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000255
- to stream Istex, to step Curation: 000255
- to stream Istex, to step Checkpoint: 000179
- to stream PubMed, to step Corpus: 000364
- to stream PubMed, to step Curation: 000364
- to stream PubMed, to step Checkpoint: 000364
- to stream Ncbi, to step Merge: 000332
- to stream Ncbi, to step Curation: 000332
- to stream Ncbi, to step Checkpoint: 000332
- to stream Main, to step Merge: 000A60
- to stream PascalFrancis, to step Corpus: 000052
- to stream PascalFrancis, to step Curation: 000085
- to stream PascalFrancis, to step Checkpoint: 000043
- to stream Main, to step Merge: 000B31
- to stream Main, to step Curation: 000A47
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Impact of Acyclovir on Genital and Plasma HIV-1 RNA, Genital Herpes Simplex Virus Type 2 DNA, and Ulcer Healing among HIV-1–Infected African Women with Herpes Ulcers: A Randomized Placebo-Controlled Trial</title><author><name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name></author><author><name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérôme" last="Legoff">Jérôme Legoff</name></author><author><name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A." last="Weiss">Helen A. Weiss</name></author><author><name sortKey="Gresenguet, Gerard" sort="Gresenguet, Gerard" uniqKey="Gresenguet G" first="Gérard" last="Grésenguet">Gérard Grésenguet</name></author><author><name sortKey="Nzambi, Khonde" sort="Nzambi, Khonde" uniqKey="Nzambi K" first="Khonde" last="Nzambi">Khonde Nzambi</name></author><author><name sortKey="Bouhlal, Hicham" sort="Bouhlal, Hicham" uniqKey="Bouhlal H" first="Hicham" last="Bouhlal">Hicham Bouhlal</name></author><author><name sortKey="Frost, Eric" sort="Frost, Eric" uniqKey="Frost E" first="Eric" last="Frost">Eric Frost</name></author><author><name sortKey="Pepin, Jacques" sort="Pepin, Jacques" uniqKey="Pepin J" first="Jacques" last="Pépin">Jacques Pépin</name></author><author><name sortKey="Malkin, Jean Elie" sort="Malkin, Jean Elie" uniqKey="Malkin J" first="Jean-Elie" last="Malkin">Jean-Elie Malkin</name></author><author><name sortKey="Hayes, Richard J" sort="Hayes, Richard J" uniqKey="Hayes R" first="Richard J." last="Hayes">Richard J. Hayes</name></author><author><name sortKey="Mabey, David C W" sort="Mabey, David C W" uniqKey="Mabey D" first="David C. W." last="Mabey">David C. W. Mabey</name></author><author><name sortKey="Belec, Laurent" sort="Belec, Laurent" uniqKey="Belec L" first="Laurent" last="Bélec">Laurent Bélec</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A8D7F03BC8675B8AACE47022187702C7B7DE22EE</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1086/599991</idno><idno type="url">https://api.istex.fr/document/A8D7F03BC8675B8AACE47022187702C7B7DE22EE/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000255</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000255</idno><idno type="wicri:Area/Istex/Curation">000255</idno><idno type="wicri:Area/Istex/Checkpoint">000179</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000179</idno><idno type="wicri:doubleKey">0022-1899:2009:Mayaud P:impact:of:acyclovir</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19530940</idno><idno type="wicri:Area/PubMed/Corpus">000364</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000364</idno><idno type="wicri:Area/PubMed/Curation">000364</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000364</idno><idno type="wicri:Area/PubMed/Checkpoint">000364</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000364</idno><idno type="wicri:Area/Ncbi/Merge">000332</idno><idno type="wicri:Area/Ncbi/Curation">000332</idno><idno type="wicri:Area/Ncbi/Checkpoint">000332</idno><idno type="wicri:doubleKey">0022-1899:2009:Mayaud P:impact:of:acyclovir</idno><idno type="wicri:Area/Main/Merge">000A60</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0339639</idno><idno type="wicri:Area/PascalFrancis/Corpus">000052</idno><idno type="wicri:Area/PascalFrancis/Curation">000085</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000043</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000043</idno><idno type="wicri:doubleKey">0022-1899:2009:Mayaud P:impact:of:acyclovir</idno><idno type="wicri:Area/Main/Merge">000B31</idno><idno type="wicri:Area/Main/Curation">000A47</idno><idno type="wicri:Area/Main/Exploration">000A47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Impact of Acyclovir on Genital and Plasma HIV-1 RNA, Genital Herpes Simplex Virus Type 2 DNA, and Ulcer Healing among HIV-1–Infected African Women with Herpes Ulcers: A Randomized Placebo-Controlled Trial</title><author><name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name><affiliation></affiliation><affiliation wicri:level="1"><country>Royaume-Uni</country><wicri:regionArea>Reprints or correspondence: Philippe Mayaud, Clinical Research Unit, London School of Hygiene & Tropical Medicine, Keppel St., London WC1E 7HT</wicri:regionArea><wicri:noRegion>London WC1E 7HT</wicri:noRegion></affiliation></author><author><name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérôme" last="Legoff">Jérôme Legoff</name><affiliation></affiliation><affiliation><wicri:noCountry code="subField">and</wicri:noCountry></affiliation></author><author><name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A." last="Weiss">Helen A. Weiss</name><affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">Royaume-Uni</country><wicri:regionArea>Infectious Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Gresenguet, Gerard" sort="Gresenguet, Gerard" uniqKey="Gresenguet G" first="Gérard" last="Grésenguet">Gérard Grésenguet</name><affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">République centrafricaine</country><wicri:regionArea>Centre National de Référence des Maladies Sexuellement Transmissibles et du SIDA de Bangui and Unité de Recherches et d’Intervention sur les Maladies Sexuellement Transmissibles et du SIDA, Faculté des Sciences de la Santé, Bangui</wicri:regionArea><wicri:noRegion>Bangui</wicri:noRegion></affiliation></author><author><name sortKey="Nzambi, Khonde" sort="Nzambi, Khonde" uniqKey="Nzambi K" first="Khonde" last="Nzambi">Khonde Nzambi</name><affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">Ghana</country><wicri:regionArea>West African Project To Combat AIDS and STIs, Accra</wicri:regionArea><placeName><settlement type="city">Accra</settlement><region nuts="2">Région du Grand Accra</region></placeName></affiliation></author><author><name sortKey="Bouhlal, Hicham" sort="Bouhlal, Hicham" uniqKey="Bouhlal H" first="Hicham" last="Bouhlal">Hicham Bouhlal</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Frost, Eric" sort="Frost, Eric" uniqKey="Frost E" first="Eric" last="Frost">Eric Frost</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre for International Health, University of Sherbrooke, Sherbrooke</wicri:regionArea><wicri:noRegion>Sherbrooke</wicri:noRegion></affiliation></author><author><name sortKey="Pepin, Jacques" sort="Pepin, Jacques" uniqKey="Pepin J" first="Jacques" last="Pépin">Jacques Pépin</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Centre for International Health, University of Sherbrooke, Sherbrooke</wicri:regionArea><wicri:noRegion>Sherbrooke</wicri:noRegion></affiliation></author><author><name sortKey="Malkin, Jean Elie" sort="Malkin, Jean Elie" uniqKey="Malkin J" first="Jean-Elie" last="Malkin">Jean-Elie Malkin</name><affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">France</country><wicri:regionArea>Centre Médical, Institut Pasteur, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Hayes, Richard J" sort="Hayes, Richard J" uniqKey="Hayes R" first="Richard J." last="Hayes">Richard J. Hayes</name><affiliation wicri:level="3"><country xml:lang="fr" wicri:curation="lc">Royaume-Uni</country><wicri:regionArea>Infectious Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Mabey, David C W" sort="Mabey, David C W" uniqKey="Mabey D" first="David C. W." last="Mabey">David C. W. Mabey</name><affiliation><wicri:noCountry code="subField">and</wicri:noCountry></affiliation></author><author><name sortKey="Belec, Laurent" sort="Belec, Laurent" uniqKey="Belec L" first="Laurent" last="Bélec">Laurent Bélec</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Infectious Diseases</title><title level="j" type="abbrev">The Journal of Infectious Diseases</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date type="published" when="2009-07-15">2009-07-15</date><biblScope unit="volume">200</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="216">216</biblScope><biblScope unit="page" to="226">226</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>Aciclovir</term><term>Acyclovir (therapeutic use)</term><term>Adolescent</term><term>Adult</term><term>Antiviral</term><term>Antiviral Agents (therapeutic use)</term><term>Central African Republic (epidemiology)</term><term>DNA, Viral (metabolism)</term><term>Double-Blind Method</term><term>Female</term><term>Genital herpes</term><term>Ghana (epidemiology)</term><term>HIV Infections (complications)</term><term>HIV Infections (virology)</term><term>HIV-1 (genetics)</term><term>HIV-1 (metabolism)</term><term>HIV-1 virus</term><term>Herpes Genitalis (complications)</term><term>Herpes Genitalis (drug therapy)</term><term>Herpes Genitalis (epidemiology)</term><term>Herpesvirus 2, Human (genetics)</term><term>Herpesvirus 2, Human (metabolism)</term><term>Human</term><term>Human herpesvirus 2</term><term>Humans</term><term>Microbiology</term><term>RNA, Viral (blood)</term><term>RNA, Viral (metabolism)</term><term>Ulcer</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral (métabolisme)</term><term>ARN viral (métabolisme)</term><term>ARN viral (sang)</term><term>Aciclovir (usage thérapeutique)</term><term>Adolescent</term><term>Adulte</term><term>Antiviraux (usage thérapeutique)</term><term>Femelle</term><term>Ghana (épidémiologie)</term><term>Herpès génital ()</term><term>Herpès génital (traitement médicamenteux)</term><term>Herpès génital (épidémiologie)</term><term>Herpèsvirus humain de type 2 (génétique)</term><term>Herpèsvirus humain de type 2 (métabolisme)</term><term>Humains</term><term>Infections à VIH ()</term><term>Infections à VIH (virologie)</term><term>Méthode en double aveugle</term><term>République centrafricaine (épidémiologie)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>DNA, Viral</term><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acyclovir</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Central African Republic</term><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Herpes Genitalis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Herpes Genitalis</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Herpes Genitalis</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term><term>Herpesvirus 2, Human</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Herpèsvirus humain de type 2</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>HIV-1</term><term>Herpesvirus 2, Human</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ADN viral</term><term>ARN viral</term><term>Herpèsvirus humain de type 2</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>ARN viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Herpès génital</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Aciclovir</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Ghana</term><term>Herpès génital</term><term>République centrafricaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Femelle</term><term>Herpès génital</term><term>Humains</term><term>Infections à VIH</term><term>Méthode en double aveugle</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Aciclovir</term><term>Antiviral</term><term>Femelle</term><term>Herpesvirus hominis 2</term><term>Herpès génital</term><term>Homme</term><term>Microbiologie</term><term>SIDA</term><term>Ulcère</term><term>Virus HIV1</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term><term>République centrafricaine</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">BackgroundLittle is known about the impact of episodic treatment of herpes on human immunodeficiency virus type 1 (HIV-1) MethodsWomen from Ghana and the Central African Republic who had genital ulcers were enrolled in a randomized, double-blind, placebo-controlled trial of acyclovir plus antibacterials and were monitored for 28 days. Ulcer etiologies and detection of lesional HIV-1 RNA were determined by polymerase chain reaction (PCR). Cervicovaginal HIV-1 RNA and herpes simplex virus type 2 (HSV-2) DNA and plasma HIV-1 RNA were quantitated by real-time PCR. Primary analyses included 118 HIV-1–infected women with HSV-2 ulcers (54 of whom were given acyclovir and 64 of whom were given placebo) ResultsAcyclovir had little impact on (1) detection of cervicovaginal HIV-1 RNA (risk ratio [RR], 0.96; 95% confidence interval [CI], 0.8–1.2) at day 7 of treatment, (2) the mean cervicovaginal HIV-1 RNA load (−0.06 log10 copies/mL; 95% CI, −0.4 to 0.3 log10 copies/mL) at day 7 of treatment, or (3) the plasma HIV-1 RNA load (+0.09 log10 copies/mL; 95% CI, −0.1 to 0.3 log10 copies/mL) at day 14 of treatment. At day 7, women receiving acyclovir were less likely to have detectable lesional HIV-1 RNA (RR, 0.70; 95% CI, 0.4–1.2) or cervicovaginal HSV-2 DNA (RR, 0.69; 95% CI, 0.4–1.3), had a lower quantity of HSV-2 DNA (−0.99 log10 copies/mL; 95% CI, −1.8 to −0.2 log10 copies/mL), and were more likely to have a healed ulcer (RR, 1.26; 95% CI, 0.9–1.9) ConclusionEpisodic therapy for herpes reduced the quantity of cervicovaginal HSV-2 DNA and slightly improved ulcer healing, but it did not decrease genital and plasma HIV-1 RNA loads Trial registrationClinicalTrials.gov identifier NCT00158483</div></front></TEI><affiliations><list><country><li>Canada</li><li>France</li><li>Ghana</li><li>Royaume-Uni</li><li>République centrafricaine</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Région du Grand Accra</li><li>Île-de-France</li></region><settlement><li>Accra</li><li>Londres</li><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Belec, Laurent" sort="Belec, Laurent" uniqKey="Belec L" first="Laurent" last="Bélec">Laurent Bélec</name><name sortKey="Bouhlal, Hicham" sort="Bouhlal, Hicham" uniqKey="Bouhlal H" first="Hicham" last="Bouhlal">Hicham Bouhlal</name><name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérôme" last="Legoff">Jérôme Legoff</name><name sortKey="Mabey, David C W" sort="Mabey, David C W" uniqKey="Mabey D" first="David C. W." last="Mabey">David C. W. Mabey</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name></noRegion><name sortKey="Hayes, Richard J" sort="Hayes, Richard J" uniqKey="Hayes R" first="Richard J." last="Hayes">Richard J. Hayes</name><name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A." last="Weiss">Helen A. Weiss</name></country><country name="République centrafricaine"><noRegion><name sortKey="Gresenguet, Gerard" sort="Gresenguet, Gerard" uniqKey="Gresenguet G" first="Gérard" last="Grésenguet">Gérard Grésenguet</name></noRegion></country><country name="Ghana"><region name="Région du Grand Accra"><name sortKey="Nzambi, Khonde" sort="Nzambi, Khonde" uniqKey="Nzambi K" first="Khonde" last="Nzambi">Khonde Nzambi</name></region></country><country name="Canada"><noRegion><name sortKey="Frost, Eric" sort="Frost, Eric" uniqKey="Frost E" first="Eric" last="Frost">Eric Frost</name></noRegion><name sortKey="Pepin, Jacques" sort="Pepin, Jacques" uniqKey="Pepin J" first="Jacques" last="Pépin">Jacques Pépin</name></country><country name="France"><region name="Île-de-France"><name sortKey="Malkin, Jean Elie" sort="Malkin, Jean Elie" uniqKey="Malkin J" first="Jean-Elie" last="Malkin">Jean-Elie Malkin</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A8D7F03BC8675B8AACE47022187702C7B7DE22EE
|texte= Impact of Acyclovir on Genital and Plasma HIV-1 RNA, Genital Herpes Simplex Virus Type 2 DNA, and Ulcer Healing among HIV-1–Infected African Women with Herpes Ulcers: A Randomized Placebo-Controlled Trial
}}
| This area was generated with Dilib version V0.6.31. |  |